JPRN-UMIN000004288已完成4 期
Combination Therapy of Olmesartan and Azelnidipine or Valsartan and Amlodipine in Hypertensinve Patients Study - COAST
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Subjects with cardiogenic shock or a SBP of <80 mmHg. (2) Subjects with serious arrhythmia (such as persistent ventricular tachycardia and ventricular fibrillation), bradycardia (<50 beat/min), or second-degree or greater atrioventricular block. (3) Subjects who have developed acute cardiac infarction within 3 months prior to informed consent. (4) Subjects with unstable angina, coronary spastic angina, or angina at rest. (5) Subjects who have undergone CABG or PCI within 3 months prior to informed consent or are going to undergo CABG or PCI during the study. (6) Subjects who have developed cerebrovascular disorders (such as cerebral hemorrhage and subarachnoid hemorrhage) within 6 months prior to informed consent. (7) Subjects with bronchial asthma or other chronic respiratory disease and cor pulmonale. (8) Subjects with a history of disease with a serious prognosis such as advanced cancer within 5 years prior to informed consent. (9) Subjects with arteriosclerosis obliterans (stage II or greater in Leriche Fontaine's classification). (10) Subjects with poorly controlled diabetes mellitus (subjects with an HbAlc of >=8.0% even in antidiabetic treatment). (11) Subjects with the following serious complications: renal disorder (e.g., persistent creatinine of >=3.0 mg/dL), hepatic disorder (e.g., persistent AST or ALT of >=100 units), and anemia (e.g., persistent Hb of <=8.0 mg/dL). (12) Subjects with thyroid dysfunction difficult to control with treatment. (13) Pregnant and lactating women, women of childbearing potential, or women who want to get pregnant during the study. (14) Subjects with a history of hypersensitivity to olmesartan, valsartan, azelnidipine, and/or amlodipine. (15) Subjects for whom the administration of olmesartan, valsartan, azelnidipine, and/or amlodipine is contraindicated. (16) Subjects who are unable to give informed consent in writing. (17) Subjects judged by the investigator to be ineligible for the study due to other reasons.
研究者
相似试验
已完成
不适用
The combined therapy with Olmesartan and Azelnidipin in the hypertensive patients with sleep apnea syndrome (SAS)Sleep Apnea SyndromeJPRN-UMIN000007171Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University100
已完成
不适用
Randomized trial of olmesartan and azelnidipine for treatment of hypertension with chronic kidney diseasehypertension with CKDJPRN-UMIN000006920Division of Nephrology, Juntendo University100
已完成
不适用
Effect of co-administration of Olmesartan and Azelnidipine on vascular endothelial function in patients with atherosclerosis-prone conditions.Patients with hypertension and atherosclerosis-prone conditions.JPRN-UMIN000004479Kitasato University School of Medicine, Cardioangiology20
已完成
不适用
Randomized study to compare olmesartan + azelnidipine versus valsartan + amlodipine to maximize blood pressure control and organ protectioHypertensionJPRN-UMIN000006605Kyoto Prefectural University School of Medicine50
尚未招募
不适用
Comparison of effects of azilsartan and olmesartan in paitents with type 2 diabetes mellitus with hypertension: A crossover trial.Patients with type 2 diabetes mellitus with hypertensionJPRN-UMIN000012619Juntendo University Graduate School of Medicine,Department of Metabolism & Endocrinology38